Trial
NCT03031470
Pilot Study of Reparixin for Early Allograft Dysfunction Prevention in Liver Transplantation
Phase IITERMINATEDSAFETYConfidence: MEDIUM
Sponsor
Dompé Farmaceutici S.p.A
Collaborators
—
Condition
Ischemia-reperfusion Injury in Liver Transplant
Intervention
Reparixin
Why stopped
Taking into account that 5 out of 22 patients in the Reparixin group experienced EAD during the first stage of the study, according to the Protocol and the DMC conclusion, it was decided on the early termination of the study
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-01-07